Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

1. Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan.Journal of the Chinese Medical Association : JCMA · 2024
   Article
2. Immunological effects of radiopharmaceutical therapy.Frontiers in nuclear medicine · 2024
   Review
3. The Curies' element: state of the art and perspectives on the use of radium in nuclear medicine.EJNMMI radiopharmacy and chemistry · 2023
   Review
4. Treatment outcomes of radium-223 in patients with metastatic castration-resistant prostate cancer: An experience before National Health Insurance reimbursement in Taiwan.Journal of the Chinese Medical Association : JCMA · 2023
   Article
5. Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report.Frontiers in oncology · 2022
   Article
6. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.Molecules (Basel, Switzerland) · 2021
   Review
7. Bone metastases: a comprehensive review of the literature.Molecular biology reports · 2020
   Review
8. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review.Cancer cell international · 2020
   Review
9. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223.Cancer reports (Hoboken, N.J.) · 2019
   Article
10. Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report.Molecular and clinical oncology · 2019
    Article
11. Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice.Oncology letters · 2019
    Article
12. Usefulness of radium-223 in patients with bone metastases.Proceedings (Baylor University. Medical Center) · 2017
    Review
13. Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?World journal of nuclear medicine
    Article
14. Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis.Autopsy & case reports
    Article
15. Ra223 in Bone Metastases with Osteolytic Activity.World journal of nuclear medicine
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.